ObjectiveFive-year net survival and conditional survival from vulvar squamous cell carcinoma (VSCC) in Italy have shown no progress during the past three decades. This study aims to estimate the complete prevalence and multiple indicators of cure for VSCC patients. MethodsObserved prevalence was estimated using 31 Italian cancer registries covering 47% of Italian women. A subset of 22 cancer registries was used to estimate model-based long-term survival and indicators of cure: complete prevalence, the cure fraction (CF), the time to cure (TTC), the proportion of 'already cured' patients, and the cure prevalence. ResultsIn 2018, VSCC patients alive in Italy (complete prevalence) were 6,620 or 22 per 100,000 women. The cure fraction (the proportion of newly diagnosed patients who will not die of VSCC) did not change between 2000 and 2010 both for all patients (32%) and in each age group. The time to cure (5-year conditional net survival >95%) was 11 years for patients aged ≥44 years, but excess mortality remained for >15 years in the other age groups. This led to a negligible (5%) proportion of ‘already cured’ patients (living longer than time to cure). The proportion of patients alive <2 years (21%) was the same as that of patients surviving ≥15 years. The cure prevalence (patients who will not die of VSCC) was 64%. A considerable proportion of patients will not be cured even among those who survived ≥5 years. ConclusionThere is an urgent need to reshape the current vulvar care model in Italy.